EXOME

all the information, none of the junk | biotech • healthcare • life sciences

Tour of Texas: Technium, Vapogenix, StemBioSys, & OneTeam Collective

Xconomy Texas — 

Let’s get caught up with the latest innovation news from Xconomy Texas.

—Dallas-based Technium has launched as a big data analytics platform to match entrepreneurs with intellectual property ready to be commercialized. The startup has built a database of patents and what co-founder Jonathan Van calls “scout software” that analyzes and serves up intellectual property according to what a founder is looking for. Technium then relies on a roster of experts who further assess the IP candidates.

—Houston biotech Vapogenix announced it raised $8.2 million to pay for Phase 2 clinical trials of its rapidly acting topical analgesic, as an alternative to opioid painkillers. The Series C funding round brings the total amount raised by Vapogenix to $18.2 million. Previous investor Pamoja Capital of Switzerland participated in the round, as well as several individual investors, the company reported.

DivInc, an Austin accelerator focused on founders who are women and/or underrepresented minorities, held its first demo day featuring innovations in e-retail, fintech, and edtech, among other sectors. DivInc founder Preston James said he was inspired to start the accelerator after failing to see diverse faces in Austin’s tech community.

—The Texas Medical Center has a new partnership with Australian hospitals to create an exchange program for health IT startups. The TMC’s program with the Health Informatics Society of Australia is called BioBridge and allows Australian entrepreneurs to apply for six-month programs with TMC member hospitals and other institutions. In exchange, American companies can seek expansion opportunities in Australia.

—Cytocentrics, a San Antonio maker of instruments used to screen if and how cells might react to drugs, has changed its name to CytoBioscience. The company’s lead device, called the CytoPatch, automates the process of measuring the reaction that cells’ ion channels have to various drug compounds, which helps researchers determine how a given compound might help or harm a cell.

StemBioSys, a small life sciences firm that sells stem cell products, raised $2.7 million in equity and debt. The San Antonio company is also in the process of raising another $3 million in equity funding. (It has raised about half of that amount so far.) StemBioSys, which has developed an extracellular matrix used to replicate stems cells, plans to use the funding for launching new products in 2017 and toward global distribution deals.

—The OneTeam Collective—made up of Kleiner Perkins Caufield Byers, Intel, the Harvard Innovation Lab, LeadDog Marketing Group, Madrona Venture Group, and Sports Innovation Lab—are looking to invest in startups related to sports, technology, and media. This venture group was started by the National Football League players union and designed to trade the rights to players’ images for equity in sports-related startups, Bloomberg reported. The OneTeam Collective will host its first pitch day in Houston in February when the city hosts the Super Bowl.